Charles River Laboratories International Inc.

230.21+6.73+3.01%Vol 411.29K1Y Perf -31.13%
May 26th, 2022 16:00 DELAYED
BID91.86 ASK259.99
Open225.50 Previous Close230.21
Pre-Market- After-Market230.21
 - -  - -%
Target Price
359.11 
Analyst Rating
Strong Buy 1.25
Potential %
55.99 
Finscreener Ranking
★★★     49.41
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     47.81
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     59.55
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
5.36 
Earnings Rating
Buy
Market Cap11.70B 
Earnings Date
4th May 2022
Alpha0.01 Standard Deviation0.09
Beta1.27 

Today's Price Range

224.16231.27

52W Range

217.20460.21

5 Year PE Ratio Range

18.9063.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.04%
1 Month
-3.66%
3 Months
-22.27%
6 Months
-38.66%
1 Year
-31.13%
3 Years
77.22%
5 Years
148.61%
10 Years
585.97%

TickerPriceChg.Chg.%
CRL230.216.73003.01
AAPL143.783.26002.32
GOOG2 165.9249.13002.32
MSFT265.903.38001.29
XOM96.640.34000.35
WFC45.601.48003.35
JNJ179.46-0.1600-0.09
FB191.637.80004.24
GE77.012.48003.33
JPM129.442.20001.73
Financial StrengthValueIndustryS&P 500US Markets
1.00
1.30
0.53
1.14
10.80
Leverage Ratio 2.80
ProfitabilityValueIndustryS&P 500US Markets
37.60
15.90
23.60
14.70
11.84
RevenueValueIndustryS&P 500US Markets
3.63B
71.44
13.23
14.96
Earnings HistoryEstimateReportedSurprise %
Q01 20222.712.751.48
Q04 20212.422.492.89
Q03 20212.572.705.06
Q02 20212.392.619.20
Q01 20212.192.5315.53
Q04 20202.122.3912.74
Q03 20201.802.3329.44
Q02 20201.271.5824.41
Earnings Per EndEstimateRevision %Trend
6/2022 QR2.830.00-
9/2022 QR2.94-2.00Negative
12/2022 FY11.63-0.09Negative
12/2023 FY13.39-0.89Negative
Next Report Date-
Estimated EPS Next Report2.71
Estimates Count7
EPS Growth Next 5 Years %14.00
Volume Overview
Volume411.29K
Shares Outstanding50.80K
Shares Float39.37M
Trades Count14.23K
Dollar Volume93.58M
Avg. Volume541.69K
Avg. Weekly Volume427.16K
Avg. Monthly Volume642.01K
Avg. Quarterly Volume555.89K

Charles River Laboratories International Inc. (NYSE: CRL) stock closed at 230.21 per share at the end of the most recent trading day (a 3.01% change compared to the prior day closing price) with a volume of 411.29K shares and market capitalization of 11.70B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 18400 people. Charles River Laboratories International Inc. CEO is James C. Foster.

The one-year performance of Charles River Laboratories International Inc. stock is -31.13%, while year-to-date (YTD) performance is -38.9%. CRL stock has a five-year performance of 148.61%. Its 52-week range is between 217.195 and 460.21, which gives CRL stock a 52-week price range ratio of 5.36%

Charles River Laboratories International Inc. currently has a PE ratio of 28.30, a price-to-book (PB) ratio of 4.53, a price-to-sale (PS) ratio of 3.24, a price to cashflow ratio of 17.30, a PEG ratio of 2.32, a ROA of 6.73%, a ROC of 9.15% and a ROE of 18.08%. The company’s profit margin is 11.84%, its EBITDA margin is 23.60%, and its revenue ttm is $3.63 Billion , which makes it $71.44 revenue per share.

Of the last four earnings reports from Charles River Laboratories International Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.71 for the next earnings report. Charles River Laboratories International Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Charles River Laboratories International Inc. is Strong Buy (1.25), with a target price of $359.11, which is +55.99% compared to the current price. The earnings rating for Charles River Laboratories International Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Charles River Laboratories International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Charles River Laboratories International Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.86, ATR14 : 11.03, CCI20 : -109.78, Chaikin Money Flow : -0.04, MACD : -10.87, Money Flow Index : 22.81, ROC : -2.35, RSI : 37.59, STOCH (14,3) : 20.46, STOCH RSI : 0.13, UO : 45.92, Williams %R : -79.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Charles River Laboratories International Inc. in the last 12-months were: Birgit Girshick (Sold 4 850 shares of value $2 133 884 ), David R. Smith (Option Excercise at a value of $1 224 594), David R. Smith (Sold 10 715 shares of value $3 245 875 ), Deborah T. Kochevar (Option Excercise at a value of $417 005), Deborah T. Kochevar (Sold 3 526 shares of value $1 433 070 ), George E. Massaro (Option Excercise at a value of $417 005), George E. Massaro (Sold 2 687 shares of value $1 157 634 ), James C. Foster (Option Excercise at a value of $6 462 233), James C. Foster (Sold 76 984 shares of value $24 283 776 ), Joseph W. LaPlume (Option Excercise at a value of $65 421), Joseph W. LaPlume (Sold 5 634 shares of value $2 052 509 ), Michael Gunnar Knell (Option Excercise at a value of $302 514), Michael Gunnar Knell (Sold 2 327 shares of value $775 715 ), Richard F. Wallman (Sold 7 200 shares of value $2 108 413 ), Victoria L. Creamer (Option Excercise at a value of $1 005 330), Victoria L. Creamer (Sold 6 917 shares of value $2 872 235 ), William D. Barbo (Option Excercise at a value of $1 020 717), William D. Barbo (Sold 12 387 shares of value $4 989 751 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
9 (90.00 %)
8 (88.89 %)
Moderate Buy
1 (10.00 %)
1 (10.00 %)
1 (11.11 %)
Hold
1 (10.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.05
Strong Buy
1.06

Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

CEO: James C. Foster

Telephone: +1 781 222-6000

Address: 251 Ballardvale Street, Wilmington 01887, MA, US

Number of employees: 18 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

64%36%

Bearish Bullish

62%38%

News

Stocktwits